SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 7, 2002
OraSure Technologies, Inc.
--------------------------
(Exact name of issuer as specified in charter)
DELAWARE 1-10492 36-4370966
(State or Other (Commission (I.R.S. Employer
Jurisdiction file Identification
of Incorporation or number) Number)
Organization)
150 Webster Street
Bethlehem, Pennsylvania 18015
(Address of principal executive offices)
(610) 882-1820
(Registrant's telephone number, including area code)
Item 5 - Other Events.
OraSure Technologies, Inc. (the "Company") issued a press release on November 7,
2002, announcing the receipt of U.S. Food and Drug Administration ("FDA")
approval of the Company's OraQuick(R) Rapid HIV-1 Antibody Test for the
detection of HIV-1 antibodies in finger-stick whole blood samples. A copy of the
press release is attached to this Report as Exhibit 99 and is incorporated
herein by reference.
Signatures
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
OraSure Technologies, Inc.
Date: November 7, 2002 By: /s/ Jack E. Jerrett
-------------------------------
Jack E. Jerrett
Vice President, General Counsel
and Secretary
EXHIBIT INDEX
Exhibit
99 Press Release issued November 7, 2002 by OraSure Technologies
announcing the receipt of U.S. Food and Drug Administration
("FDA") approval of the Company's OraQuick(R) Rapid HIV-1
Antibody Test for the detection of HIV-1 antibodies in
finger-stick whole blood samples.